AstraZeneca to acquire U.S. biotech startup and strengthen vaccine development

AstraZeneca announced that it would acquire U.S. biotech startup OmniOse and strengthen its infectious disease development capabilities. The acquisition was announced on the 10th.

Full text unavailableWorking from the headline and excerpt

sources corroborateOutlets reporting the same event

companies linkedAcross 0 themes, second pass

The story

U.K. pharmaceutical giant AstraZeneca disclosed plans to acquire U.S. biotechnology startup OmniOse and integrate its business into AstraZeneca's infectious disease division. The acquisition was announced on the 10th.

The acquisition is expected to bring OmniOse's technologies and personnel into AstraZeneca's infectious disease research and development organization, potentially strengthening the company's vaccine development capabilities.

At a glance

Company nameAcquisition of OmniOse by AstraZeneca

TradingAcquired OmniOse

TimingAnnounced on the 10th

IntegrationIntegrated into the infectious disease division

Reference information. Every claim resolves to something the story actually named.

Where this came from

We read each source in full and checked they agree on the core claim.

1/ 1 agree

All of them report the same thing.

google.comNews

AgreesOpen

Read the original articleGo to the source page

Reference information generated from public sources. It does not solicit or advise on investments. Prices are 15-minute delayed.